about
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.Herpes simplex virus type 2 ascending myeloradiculitis: MRI findings and rapid diagnosis by the polymerase chain method.Successful treatment of subcorneal pustular dermatosis (Sneddon-wilkinson disease) by acitretin: report of a case.Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease.Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines.Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythrodermaFrequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid PapulosisConstitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa.Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature.Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review.Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus.Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type.Defining and recognising locally advanced basal cell carcinoma.A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines: A Useful Model for Rapid Biological and Therapeutic Evaluation.Risk factors, clinical variants and therapeutic outcome of retronychia: a retrospective study of 18 patients.First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma.Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy.Predictors of long-term drug survival for infliximab in psoriasis.[Cutaneous granular bacteriosis occurring in Staphylococcus aureus septicaemia].[Stevens-Johnson's syndrome following ingestion of gunpowder].[Lethal pulmonary involvement of neutrophilic dermatosis following erythropoietin therapy].[Cutaneous lesions during hot-tub hypersensitivity pneumonitis: Pseudomonas folliculitis ?][Latent-disseminated tuberculosis revealed by atypical skin ulcerations].[Sweet syndrome associated with Crohn disease].Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions.
P50
Q33418737-8BBE9C82-B902-4844-94A1-294105A14060Q33429707-C690D821-5189-4A04-8E81-3F14164F48F9Q33732831-D57E85B6-FF80-403A-A5AF-E5EE14407C4FQ33772473-5E94CBA1-FFD2-4007-BE11-7447570010AEQ34318219-7E45F565-5304-4932-98E0-1592D66593A7Q35188571-F2CA81D1-4BA4-4A7C-92C4-AB976A173CA3Q35199592-FD91B00E-C0CD-4881-AFA9-FFF2C128B2C8Q35199597-1747E430-F0D5-4535-9232-B5DB77BE4771Q35199602-7D4FB945-719F-4B46-939B-C6C86BC61F93Q36176283-E9C9A12E-24E8-42BC-AA58-F225B0502D35Q36310531-6B2E9D5C-7EE1-4CCD-8223-13EE27CA7701Q36452258-4795C963-90A9-4E30-9007-F47BF7A829A2Q37142178-8CAC51A1-48EC-450D-8369-FF4F048E6AA5Q37163606-5AFA7513-0706-4C63-9290-EE23F1DF6D6CQ37273194-A25A54FB-8721-4BD5-B572-8C9535056B2DQ37661276-5C50114E-9D59-40C0-B7B0-44C83A400B01Q37708848-E82D2939-1552-4B0A-A35F-1364B87C3392Q37873160-F39D3A4B-EC8F-48A8-B381-41359909EDF7Q38005946-87027AC1-278A-4FC2-AE6E-68B1A03A30BCQ38197266-4091ADBF-CBED-4DDF-8874-F0D04F8EDA5BQ38225380-83D10434-E724-44A9-9337-D4E39B32A13EQ38225381-41DAB858-F6E9-44A3-B836-23C785D9DC9EQ38520742-4538A0B5-2B7F-4E3F-9CF3-13B42375CC0DQ38609628-5E96DCFB-F67D-4F99-AB1D-B53FE2E583CDQ38635167-5EFF6C40-636D-4460-8A4F-AAEF9A4AB4D2Q38688019-86AF8A72-72DF-4B37-99C0-C37727D57FD0Q38727735-BC27219F-0B1D-4927-9D84-C4E329FCAD06Q38770720-7B8ADBA7-104E-445F-8449-5BCE4BCA539EQ38819448-904ABCFF-2251-42F8-B02F-11A51C95CDA0Q38876705-5D8E29D0-9E5D-4360-A613-BB1D47380C1CQ39029737-A9AC585A-5E2D-4A7F-83AA-6E0DFD7DD836Q39306641-D6C16593-A320-4AAB-85A2-C84CAD05BA80Q39668241-E1C824B0-6A38-4F82-8B1E-F892B10A747DQ40074812-F4199465-68FF-49B7-A8D4-2CFD00C3CC3CQ40269386-A15AC986-7F15-444B-AFE1-5DB78C5B4A22Q40419902-86216CF0-55A8-47D9-96E2-3CAFE526AE70Q40460162-C29FEF1C-7290-4A4A-93AD-2EE12F26791AQ40637487-49631A00-71D8-4B13-8204-9DADB080C206Q40690656-0C4713CC-FD8A-4DFB-A0A4-FD488D9E3923Q41390666-A016F0FA-0F8E-4440-ADD0-E5F6B7ED1144
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marie Beylot-Barry
@ast
Marie Beylot-Barry
@en
Marie Beylot-Barry
@es
Marie Beylot-Barry
@nl
Marie Beylot-Barry
@sl
type
label
Marie Beylot-Barry
@ast
Marie Beylot-Barry
@en
Marie Beylot-Barry
@es
Marie Beylot-Barry
@nl
Marie Beylot-Barry
@sl
prefLabel
Marie Beylot-Barry
@ast
Marie Beylot-Barry
@en
Marie Beylot-Barry
@es
Marie Beylot-Barry
@nl
Marie Beylot-Barry
@sl
P106
P1153
7006650722
P31
P496
0000-0001-6150-1229